B-intervention	0	4	Risk
I-intervention	5	10	Model
I-intervention	10	11	-
I-intervention	11	17	Guided
I-intervention	18	28	Antiemetic
I-intervention	29	40	Prophylaxis
O	41	43	vs
B-control	44	53	Physician
I-control	53	54	'
I-control	54	55	s
I-control	56	62	Choice
O	63	65	in
O	66	74	Patients
O	75	84	Receiving
O	85	97	Chemotherapy
O	98	101	for
O	102	107	Early
O	107	108	-
O	108	113	Stage
O	114	120	Breast
O	121	127	Cancer
O	127	128	:
O	129	130	A
O	131	141	Randomized
O	142	150	Clinical
O	151	156	Trial
O	156	157	.

O	158	165	Despite
O	166	174	multiple
O	175	182	patient
O	182	183	-
O	183	191	centered
O	192	199	factors
O	200	205	being
O	206	216	associated
O	217	221	with
O	222	225	the
O	226	230	risk
O	231	233	of
O	234	246	chemotherapy
O	246	247	-
O	247	254	induced
O	255	261	nausea
O	262	265	and
O	266	274	vomiting
O	275	276	(
O	276	280	CINV
O	280	281	)
O	281	282	,
O	283	288	these
O	289	296	factors
O	297	300	are
O	301	307	rarely
O	308	318	considered
O	319	323	when
O	324	330	making
O	331	341	antiemetic
O	342	357	recommendations
O	357	358	.

O	359	361	To
O	362	369	compare
O	370	374	risk
O	375	380	model
O	380	381	-
O	381	387	guided
O	388	389	(
O	389	392	RMG
O	392	393	)
O	394	404	antiemetic
O	405	416	prophylaxis
O	417	421	with
O	422	431	physician
O	431	432	'
O	432	433	s
O	434	440	choice
O	441	442	(
O	442	444	PC
O	444	445	)
O	446	448	in
O	449	457	patients
O	458	467	receiving
O	468	480	chemotherapy
O	481	484	for
O	485	490	early
O	490	491	-
O	491	496	stage
O	497	503	breast
O	504	510	cancer
O	510	511	.

O	512	513	A
O	514	524	randomized
O	525	533	clinical
O	534	539	trial
O	540	542	of
B-total-participants	543	546	324
B-eligibility	547	555	patients
I-eligibility	556	560	with
I-eligibility	561	566	early
I-eligibility	566	567	-
I-eligibility	567	572	stage
I-eligibility	573	579	breast
I-eligibility	580	586	cancer
I-eligibility	587	597	undergoing
I-eligibility	598	610	chemotherapy
I-eligibility	611	612	(
I-eligibility	612	628	cyclophosphamide
I-eligibility	629	632	and
I-eligibility	633	635	an
I-eligibility	636	649	anthracycline
I-eligibility	649	650	)
I-eligibility	651	654	for
I-eligibility	655	658	the
I-eligibility	659	664	first
I-eligibility	665	669	time
O	670	672	at
O	673	674	2
O	675	684	specialty
O	685	691	cancer
O	692	696	care
O	697	704	centers
O	705	707	in
B-location	708	714	Ottawa
O	715	719	from
O	720	725	April
O	726	728	10
O	728	729	,
O	730	734	2012
O	734	735	,
O	736	738	to
O	739	748	September
O	749	750	2
O	750	751	,
O	752	756	2014
O	756	757	.

O	758	766	Patients
O	767	771	were
O	772	782	randomized
O	783	785	to
O	786	792	either
O	793	796	the
O	797	800	RMG
O	801	804	arm
O	805	806	(
O	806	807	n
O	808	809	=
B-intervention-participants	810	813	154
O	813	814	)
O	815	817	or
O	818	821	the
O	822	824	PC
O	825	832	control
O	833	836	arm
O	837	838	(
O	838	839	n
O	840	841	=
B-control-participants	842	845	170
O	845	846	)
O	846	847	.

O	848	853	Prior
O	854	856	to
O	857	861	each
O	862	867	cycle
O	868	870	of
O	871	883	chemotherapy
O	884	892	patients
O	893	895	in
O	896	899	the
O	900	903	RMG
O	904	909	group
O	910	914	were
O	915	926	categorized
O	927	929	as
O	930	933	low
O	934	936	or
O	937	941	high
O	942	946	risk
O	947	950	for
O	951	955	CINV
O	955	956	,
O	957	960	and
O	961	966	their
O	967	977	antiemetic
O	978	988	treatments
O	989	993	were
O	994	1002	adjusted
O	1003	1014	accordingly
O	1014	1015	.

O	1016	1024	Patients
O	1025	1035	considered
O	1036	1038	to
O	1039	1041	be
O	1042	1044	at
O	1045	1048	low
O	1049	1053	risk
O	1054	1062	received
O	1063	1071	standard
O	1072	1085	dexamethasone
O	1086	1089	and
O	1090	1091	a
O	1092	1093	5
O	1093	1094	-
O	1094	1097	HT3
O	1098	1108	antagonist
O	1108	1109	,
O	1110	1115	while
O	1116	1121	those
O	1122	1124	at
O	1125	1129	high
O	1130	1134	risk
O	1135	1139	also
O	1140	1148	received
O	1149	1159	aprepitant
O	1160	1164	with
O	1165	1167	or
O	1168	1175	without
O	1176	1186	olanzapine
O	1186	1187	,
O	1188	1193	based
O	1194	1196	on
O	1197	1202	their
O	1203	1207	risk
O	1208	1213	level
O	1213	1214	.

O	1215	1218	The
O	1219	1221	PC
O	1222	1229	control
O	1230	1235	group
O	1236	1244	received
O	1245	1255	antiemetic
O	1256	1262	agents
O	1263	1272	according
O	1273	1275	to
O	1276	1279	the
O	1280	1288	treating
O	1289	1298	physician
O	1298	1299	'
O	1299	1300	s
O	1301	1311	discretion
O	1311	1312	.

O	1313	1316	The
O	1317	1324	primary
O	1325	1328	end
O	1329	1335	points
O	1336	1340	were
B-outcome-Measure	1341	1348	control
I-outcome-Measure	1349	1351	of
I-outcome-Measure	1352	1356	both
I-outcome-Measure	1357	1363	nausea
I-outcome-Measure	1364	1367	and
I-outcome-Measure	1368	1376	vomiting
O	1377	1379	in
O	1380	1383	the
O	1384	1389	acute
O	1390	1403	posttreatment
O	1404	1410	period
O	1411	1412	(
O	1412	1417	first
O	1418	1420	24
O	1421	1426	hours
O	1427	1432	after
O	1433	1440	therapy
O	1440	1441	)
O	1442	1445	and
O	1446	1448	in
O	1449	1452	the
O	1453	1460	delayed
O	1461	1474	posttreatment
O	1475	1481	period
O	1482	1483	(
O	1483	1487	days
O	1488	1489	2
O	1489	1490	-
O	1490	1491	5
O	1492	1497	after
O	1498	1505	therapy
O	1505	1506	)
O	1506	1507	.

O	1508	1511	The
O	1512	1517	total
O	1518	1525	numbers
O	1526	1528	of
O	1529	1541	chemotherapy
O	1542	1548	cycles
O	1549	1558	delivered
O	1559	1561	in
O	1562	1565	the
O	1566	1569	RMG
O	1570	1573	and
O	1574	1576	PC
O	1577	1584	control
O	1585	1591	groups
O	1592	1596	were
O	1597	1600	497
O	1601	1604	and
O	1605	1608	551
O	1609	1621	respectively
O	1621	1622	.

B-outcome	1623	1625	In
I-outcome	1626	1629	the
I-outcome	1630	1635	acute
I-outcome	1636	1642	period
O	1642	1643	,
O	1644	1657	significantly
O	1658	1662	more
O	1663	1671	patients
O	1672	1674	in
O	1675	1678	the
O	1679	1682	RMG
O	1683	1688	group
O	1689	1697	reported
B-outcome	1698	1700	no
I-outcome	1701	1707	nausea
O	1708	1709	(
B-iv-bin-percent	1709	1711	53
I-iv-bin-percent	1711	1712	.
I-iv-bin-percent	1712	1713	7
I-iv-bin-percent	1713	1714	%
O	1715	1716	[
O	1716	1718	95
O	1718	1719	%
O	1720	1722	CI
O	1722	1723	,
O	1724	1726	49
O	1726	1727	.
O	1727	1728	2
O	1728	1729	%
O	1729	1730	-
O	1730	1732	58
O	1732	1733	.
O	1733	1734	1
O	1734	1735	%
O	1735	1736	]
O	1737	1739	vs
B-cv-bin-percent	1740	1742	41
I-cv-bin-percent	1742	1743	.
I-cv-bin-percent	1743	1744	6
I-cv-bin-percent	1744	1745	%
O	1746	1747	[
O	1747	1749	95
O	1749	1750	%
O	1751	1753	CI
O	1753	1754	,
O	1755	1757	37
O	1757	1758	.
O	1758	1759	4
O	1759	1760	%
O	1760	1761	-
O	1761	1763	45
O	1763	1764	.
O	1764	1765	3
O	1765	1766	%
O	1766	1767	]
O	1767	1768	;
O	1769	1770	P
O	1771	1772	<
O	1773	1774	.
O	1774	1777	001
O	1777	1778	)
O	1779	1782	and
B-outcome	1783	1785	no
I-outcome	1786	1794	vomiting
O	1795	1796	(
B-iv-bin-percent	1796	1798	91
I-iv-bin-percent	1798	1799	.
I-iv-bin-percent	1799	1800	8
I-iv-bin-percent	1800	1801	%
O	1802	1803	[
O	1803	1805	95
O	1805	1806	%
O	1807	1809	CI
O	1809	1810	,
O	1811	1813	89
O	1813	1814	.
O	1814	1815	0
O	1815	1816	%
O	1816	1817	-
O	1817	1819	94
O	1819	1820	.
O	1820	1821	0
O	1821	1822	%
O	1822	1823	]
O	1824	1826	vs
B-cv-bin-percent	1827	1829	82
I-cv-bin-percent	1829	1830	.
I-cv-bin-percent	1830	1831	2
I-cv-bin-percent	1831	1832	%
O	1833	1834	[
O	1834	1836	95
O	1836	1837	%
O	1838	1840	CI
O	1840	1841	,
O	1842	1844	78
O	1844	1845	.
O	1845	1846	8
O	1846	1847	%
O	1847	1848	-
O	1848	1850	85
O	1850	1851	.
O	1851	1852	3
O	1852	1853	%
O	1853	1854	]
O	1854	1855	;
O	1856	1857	P
O	1858	1859	<
O	1860	1861	.
O	1861	1864	001
O	1864	1865	)
O	1866	1874	compared
O	1875	1879	with
O	1880	1883	the
O	1884	1886	PC
O	1887	1894	control
O	1895	1900	group
O	1900	1901	.

O	1902	1911	Similarly
O	1911	1912	,
O	1913	1926	significantly
O	1927	1931	more
O	1932	1940	patients
O	1941	1943	in
O	1944	1947	the
O	1948	1951	RMG
O	1952	1957	group
O	1958	1966	reported
B-outcome	1967	1969	no
I-outcome	1970	1976	nausea
O	1977	1978	(
B-iv-bin-percent	1978	1980	39
I-iv-bin-percent	1980	1981	.
I-iv-bin-percent	1981	1982	6
I-iv-bin-percent	1982	1983	%
O	1984	1985	[
O	1985	1987	95
O	1987	1988	%
O	1989	1991	CI
O	1991	1992	,
O	1993	1995	35
O	1995	1996	.
O	1996	1997	3
O	1997	1998	%
O	1998	1999	-
O	1999	2001	44
O	2001	2002	.
O	2002	2003	1
O	2003	2004	%
O	2004	2005	]
O	2006	2008	vs
B-cv-bin-percent	2009	2011	30
I-cv-bin-percent	2011	2012	.
I-cv-bin-percent	2012	2013	7
I-cv-bin-percent	2013	2014	%
O	2015	2016	[
O	2016	2018	95
O	2018	2019	%
O	2020	2022	CI
O	2022	2023	,
O	2024	2026	26
O	2026	2027	.
O	2027	2028	8
O	2028	2029	%
O	2029	2030	-
O	2030	2032	34
O	2032	2033	.
O	2033	2034	7
O	2034	2035	%
O	2035	2036	]
O	2036	2037	;
O	2038	2039	P
O	2040	2041	=
O	2042	2043	.
O	2043	2045	01
O	2045	2046	)
O	2047	2050	and
B-outcome	2051	2053	no
I-outcome	2054	2062	vomiting
O	2063	2064	(
B-iv-bin-percent	2064	2066	87
I-iv-bin-percent	2066	2067	.
I-iv-bin-percent	2067	2068	1
I-iv-bin-percent	2068	2069	%
O	2070	2071	[
O	2071	2073	95
O	2073	2074	%
O	2075	2077	CI
O	2077	2078	,
O	2079	2081	83
O	2081	2082	.
O	2082	2083	8
O	2083	2084	%
O	2084	2085	-
O	2085	2087	90
O	2087	2088	.
O	2088	2089	0
O	2089	2090	%
O	2090	2091	)
O	2092	2094	vs
B-cv-bin-percent	2095	2097	78
I-cv-bin-percent	2097	2098	.
I-cv-bin-percent	2098	2099	0
I-cv-bin-percent	2099	2100	%
O	2101	2102	[
O	2102	2104	95
O	2104	2105	%
O	2106	2108	CI
O	2108	2109	,
O	2110	2112	74
O	2112	2113	.
O	2113	2114	3
O	2114	2115	%
O	2115	2116	-
O	2116	2118	81
O	2118	2119	.
O	2119	2120	4
O	2120	2121	%
O	2121	2122	]
O	2122	2123	;
O	2124	2125	P
O	2126	2127	<
O	2128	2129	.
O	2129	2132	001
O	2132	2133	)
B-outcome	2134	2136	in
I-outcome	2137	2140	the
I-outcome	2141	2148	delayed
I-outcome	2149	2155	period
O	2156	2168	respectively
O	2168	2169	.

O	2170	2172	In
O	2173	2177	this
O	2178	2183	trial
O	2183	2184	,
O	2185	2188	the
O	2189	2192	RMG
O	2193	2203	antiemetic
O	2204	2215	prophylaxis
O	2216	2219	led
O	2220	2222	to
O	2223	2231	improved
O	2232	2239	control
O	2240	2242	of
O	2243	2248	acute
O	2249	2252	and
O	2253	2260	delayed
O	2261	2265	CINV
O	2266	2274	compared
O	2275	2279	with
O	2280	2289	physician
O	2289	2290	'
O	2290	2291	s
O	2292	2298	choice
O	2299	2301	of
O	2302	2309	therapy
O	2309	2310	.
O	2311	2325	clinicaltrials
O	2325	2326	.
O	2326	2329	gov
O	2330	2340	Identifier
O	2340	2341	:
O	2342	2353	NCT01913990
O	2353	2354	.
